TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by NewEdge Advisors LLC

NewEdge Advisors LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 86.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,635 shares of the company's stock after purchasing an additional 11,406 shares during the quarter. NewEdge Advisors LLC owned approximately 0.07% of TransMedics Group worth $1,536,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TMDX. Virtu Financial LLC purchased a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $436,000. Morse Asset Management Inc purchased a new stake in TransMedics Group in the third quarter valued at $823,000. Sanctuary Advisors LLC boosted its stake in TransMedics Group by 63.4% in the third quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company's stock valued at $634,000 after acquiring an additional 1,568 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of TransMedics Group during the third quarter worth about $149,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Piper Sandler reiterated an "overweight" rating and set a $105.00 price target (up previously from $90.00) on shares of TransMedics Group in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $124.20.

TransMedics Group Stock Performance

TMDX traded down $0.49 during trading on Tuesday, reaching $89.70. The company's stock had a trading volume of 180,017 shares, compared to its average volume of 1,348,334. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 95.46 and a beta of 2.14. The company's fifty day moving average price is $74.67 and its 200-day moving average price is $77.10. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.